Science and Research

ABP: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Study details
Study-ID: NCT04318938, 2019-001828-36
Study-ID: NCT04318938, 2019-001828-36
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry, Externally - public
Funding: Externally - industry, Externally - public
DZL Participating Sites: CPC-M, BIH / Charité - Associated Partner
DZL Participating Sites: CPC-M, BIH / Charité - Associated Partner
Start Date: 30.03.2020
Completion Date: 31.12.2027
Status: Active / not recruiting
Status: Active / not recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.